Search Results
Your search for ,loW matches 7101 pages
Showing 751 - 800Expert Point of View: Aparna R. Parikh, MD
he latest findings for circulating tumor DNA (ctDNA) in colorectal cancer were discussed at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium by Aparna R. Parikh, MD, a gastrointestinal oncologist at Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard...
Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment
Circulating tumor DNA (ctDNA) has become an established biomarker of measurable or molecular residual disease (MRD) after curative-intent surgery in patients with colorectal cancer. The research focus is now on linking ctDNA to long-term outcomes and using it to guide treatment decisions—which was...
Nivolumab Plus Ipilimumab Improves Progression-Free Survival in First-Line Setting of Metastatic Colorectal Cancer
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) nonresectable or metastatic colorectal cancer derived significant benefit from an immunotherapy doublet, with nivolumab plus ipilimumab reducing the...
Inherited Genetic Factors May Influence Risk of Subsequent Cancer Diagnoses in Childhood Cancer Survivors
Investigators have found that common inherited genetic factors capable of predicting cancer risk in the general population may also help to predict childhood cancer survivors who may be at elevated risk of new cancers later in life, according to a recent study published by Gibson et al in Nature...
Physician Attitudes Toward 2020 ACS Cervical Cancer Screening Guidelines
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients...
Low-Risk Cervical Cancer: Pelvic Recurrence With Simple vs Radical Hysterectomy
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
HR-Positive/HER2-Negative Metastatic Breast Cancer With PIK3CA Mutation
This is Part 2 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification
Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented by Thorstad et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium...
Variations in Use of Chemotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in chemotherapy use among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The study...
Social Determinants of Health Potentially Responsible for Low Breast Cancer Screening Rates
Investigators may have uncovered the social determinants of health hindering breast cancer screening in the United States, according to a recent systematic review published by Jhumkhawala et al in Frontiers in Public Health. Background Health disparities have consistently been associated with...
Advanced Multiple Myeloma: Prediction Model for Outcomes After BCMA-Directed CAR T-Cell Therapy
As reported in the Journal of Clinical Oncology, Gagelmann et al have developed a predictive model (Myeloma CAR-T Relapse [MyCARe] model) for outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple...
Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer
Pooja Karukonda, MD, of Duke University Medical Center, discusses findings from the PaRTNer study, which addressed the large financial burden faced by patients with head and neck cancer undergoing radiotherapy, particularly older, non-White, female, and low-income patients. Dr. Karukonda discusses...
Novel Monotherapy in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
In an analysis reported in the Journal of Clinical Oncology, Arrillaga-Romany et al found that single-agent ONC201 (dordaviprone), a first-in-class imipridone, showed activity in recurrent histone 3 (H3) K27M-mutant diffuse midline glioma. As noted by the investigators, “H3 K27M–mutant diffuse...
Celebrating Advances in Cancer Care and a Look at How AI Is Revolutionizing Oncology
For the third year in a row, more than 250 leaders in cancer care, including cancer center directors, physicians, scientists, ethicists, journalists, public officials, and patient advocates, gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to attend the...
Gene Signature May Predict Response to Combination Therapy in Patients With NSCLC
Researchers have identified a set of 140 genes that may help predict disease-free survival in patients with non–small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation, according to a recent study published by Altorki et al in Cell Reports Medicine. The...
Highlights From the 2023 San Antonio Breast Cancer Symposium
Studies presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) significantly moved the needle forward in our treatment of breast cancer. We are increasingly learning how to stratify risk, so we can optimize therapy and minimize our patients’ exposure to treatments that will not be...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Expert Point of View: Laura Huppert, MD
Invited discussant Laura Huppert, MD, of the University of California, San Francisco, Comprehensive Cancer Center, focused her remarks on the need for biomarkers for selection of immunotherapy as part of neoadjuvant chemotherapy for hormone receptor–positive, HER2-negative breast cancer. “Hormone...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
Stool-Based Colorectal Cancer Screening: Comparison of Fecal Immunochemical Tests
In a Dutch study reported in The Lancet Oncology, Wisse et al found that a multitarget fecal immunochemical test (mtFIT) improved detection of advanced adenomas vs standard FIT in colorectal cancer screening. The mtFIT used in the study measures hemoglobin, calprotectin, and serpin family F member...
COVID-19 Risk in Pediatric Patients Receiving Treatment for Acute Lymphoblastic Leukemia or Lymphoma
In a retrospective case series reported in JAMA Network Open, Hashmi et al found that more than one-third of pediatric patients receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL) developed COVID-19 infection during a recent 2-year period. Study...
8-Year Follow-up of MINDACT Trial: Locoregional Breast Cancer Recurrence in Patients Undergoing Breast-Conserving Surgery
In a long-term analysis of the EORTC 10041/BIG 03-04 MINDACT trial reported in the Journal of Clinical Oncology, Alaeikhanehshir et al found that the 70-gene signature was not independently predictive of locoregional recurrence among women undergoing breast-conserving surgery for early breast...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
First-Line Radioligand-Based Therapy Demonstrates Benefit in Some Neuroendocrine Tumors
Adding the radioligand lutetium-177 dotatate (Lu-177 dotatate) to standard therapy almost tripled the median progression-free survival in patients with untreated, high-grade, gastroenteropancreatic neuroendocrine tumors in the randomized phase III NETTER-2 study, researchers reported at the 2024...
Metastatic Castration-Resistant Prostate Cancer: Tumor Mutational Burden and Response to Checkpoint Inhibition
In a single-center retrospective study reported as a research letter in JAMA Oncology, Zang et al found that high tumor mutational burden (TMB) was associated with better outcomes of checkpoint inhibition in patients with metastatic castration-resistant prostate cancer. Study Details The study...
Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer
ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...
All-Oral Regimen Feasible and Effective in Acute Promyelocytic Leukemia, Study Finds
An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) was shown to be “highly effective and safe,” eliminating the need for chemotherapy altogether in many patients, Hong Kong researchers reported at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Strategies to Reduce Burden of Colorectal Cancer in Latin America
Investigators may have identified colorectal cancer screening programs in Latin America, according to a recent systematic review and meta-analysis published by Montalvan-Sanchez et al in JAMA Network Open. Background Colorectal cancer—the second leading cause of cancer-related mortality...
Does Annual Breast Cancer Screening Starting at Age 40 Offer Benefit?
Investigators have found that annual breast cancer screening beginning at age 40 and continuing to at least 79 may result in the greatest reduction in mortality with minimal risks, according to a recent study published by Monticciolo et al in Radiology. Background Breast cancer is the second most...
Genetic Alterations Associated With Interval Breast Cancer Diagnosis
In a Swedish study reported in JAMA Oncology, Rodriguez et al identified characteristics of interval breast cancers—those diagnosed between two screening examinations—compared with screen-detected cancers on the basis of analysis of rare germline genetic deleterious protein-truncating variants. As...
Analysis of Cancer Diagnoses After Recent Weight Loss
In a study reported in JAMA, Wang et al found that individuals with a weight loss of more than 10% during the prior 2 years had a higher risk of cancer diagnosis over the subsequent 12 months vs those with no weight loss. Study Details The retrospective cohort analysis included women aged at least...
Expert Point of View: Dipenkumar Modi, MD
The ASCO Post obtained comments on the Smart Stop study from Dipenkumar Modi, MD, a medical oncologist and hematologist at the Barbara Ann Karmanos Cancer Institute and Assistant Professor of Oncology at Wayne State University School of Medicine, Detroit. Dr. Modi applauded the investigators for...
Expert Point of View: Carla Casulo, MD
Session co-moderator Carla Casulo, MD, offered her thoughts on the response-adapted use of ultra-low–dose radiotherapy in gastric MALT (mucosa-associated lymphoid tissue) lymphoma, as reported by the investigators from MD Anderson Cancer Center. Dr. Casulo is Associate Professor of Medicine and...
‘Ultra-Low Dose’ of Radiotherapy May Be Enough in Gastric MALT Lymphoma, Study Finds
For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...
Highlights From the 2023 ASH Annual Meeting & Exposition
Hordes of classical and malignant hematologists returned to the tranquil city of San Diego for the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition this past December. The packed agenda lit the Gaslight District up with neuron-searing data, creating an environment for...
In NPM1-Mutated AML, Benefit of Transplant Limited to Patients With Residual Disease
In patients with NPM1-mutated acute myeloid leukemia (AML), the presence of molecular measurable residual disease (MRD) in the peripheral blood following induction chemotherapy can aid decision-making about postremission therapy. More specifically, MRD status in the peripheral blood can identify...
Low-Dose Positron-Emission Mammography May Improve Breast Cancer Detection
Low-dose positron-emission mammography (PEM) may provide high sensitivity for detecting breast cancer and significantly reduce the likelihood of false-positive results, according to a recent study published by Freitas et al in Radiology: Imaging Cancer. The innovative breast imaging technique may...
All-Oral Regimen Feasible and Effective in Acute Promyelocytic Leukemia, Study Finds
An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) was shown to be “highly effective and safe,” eliminating the need for chemotherapy altogether in many patients, Hong Kong researchers reported at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Novel Biomarker in Cancer Survivors May Be Linked to Higher Risk of Mortality
Elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) levels may be associated with a higher risk of mortality among cancer survivors, according to a recent study published by Cao et al in the Journal of the National Cancer Institute. NT-proBNP—produced in response to the stretching of...
Are Major Adverse Financial Events Linked to a Later-Stage Cancer Diagnosis?
Studies have shown that millions of people in the United States are financially vulnerable because of low income, limited savings, or high levels of debt. In 2021, 32% of U.S. adults reported being unable to cover an unexpected expense of $400. A recent study by researchers at the American Cancer...
Multiplex Analysis of Intratumoral Immune Infiltrate and Prognosis in Colorectal Cancer
In an analysis reported by Frei et al in The Lancet Oncology, multiplex immunofluorescence staining of tissue microarrays of samples from patients with stage II to III colorectal cancer showed that densities of CD8-positive and Foxp3-positive cells were associated with recurrence-free interval. As...
Skin Microbiome and Severe Radiodermatitis in Patients With Breast Cancer
In a German single-institution study reported in JAMA Oncology, Hülpüsch et al identified skin microbiome characteristics associated with severe radiodermatitis in women receiving adjuvant radiotherapy for breast cancer. Study Details The study included 20 consecutively enrolled women who received...
Reflections on Cancer’s Toll on My Family
Over the past 2 years, my family and I have experienced firsthand the challenges of cancer. In the spring of 2021, my mother was diagnosed with stage IIB pancreatic cancer. She died in mid-2023 after developing metastatic disease, including peritoneal carcinomatosis. The experience has caused me to ...
Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...
Triplet Without or With Ipilimumab in Kidney Transplant Recipients With Advanced Cutaneous Cancers
In a small phase I/II trial reported in the Journal of Clinical Oncology, Schenk et al found that treatment with tacrolimus, prednisone, and nivolumab without or with ipilimumab produced few responses in kidney transplant recipients with advanced skin cancers, with treatment-related allograft loss...
Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
It has been almost 20 years since the approval of trastuzumab for the treatment of early-stage, HER2-positive breast cancer. I remember returning from the 2005 ASCO Annual Meeting excited to offer patients a treatment that led to significant improvement in clinical outcomes. However, within a short ...
Global Cancer Burden May Be Growing Amidst Mounting Need for Cancer Services
The World Health Organization’s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has released updated findings of the current global burden of cancer alongside World Cancer Day on February 4, 2023. The WHO indicated that a majority of countries do not adequately finance...
